Regulatory ImpactRegulatory Impact
Insights

Research briefs for regulatory and competitive intelligence teams

Evidence-grounded market and regulatory briefs built for fast scanning, comparison, and strategic follow-up.

Regulatory Strategy16 min read

ER-100 Phase 1 Results: Early Clinical Findings and Implications for Epigenetic Reprogramming

Life Biosciences has reported the first human safety and visual-function observations for ER-100, its investigational epigenetic reprogramming therapy. Two of three glaucoma participants demonstrated localized improvements in visual-field sensitivity after 56 days. The findings are consistent with the possibility of recovering function in damaged retinal ganglion cells, but their reproducibility and relationship to primate electrophysiology remain unresolved.

ER-100Gene TherapyEpigenetic Reprogramming
Read Brief →

Stay ahead with new regulatory insights

Get new research briefs on product, target, and competitive landscapes as they publish.

Regulatory Intelligence10 min read

FDA-Approved Products for Nausea and Vomiting of Pregnancy: Efficacy, Safety, and Regulatory Precedent

FDA approvals specifically addressing nausea and vomiting of pregnancy center on doxylamine succinate plus pyridoxine hydrochloride. The underlying reviews show a statistically significant but modest placebo-adjusted efficacy effect, extensive historical support, and a later formulation approval built primarily through pharmacokinetic bridging rather than a new efficacy trial.

FDANausea and Vomiting of PregnancyPregnancy
Read Brief →
Drug Approvals18 min read

Lumvoa for Thyroid Eye Disease: Review Findings, Treatment Landscape, and Commercial Outlook

Lumvoa (veligrotug-vvze) becomes the second FDA-approved drug specifically indicated for thyroid eye disease, adding a shorter intravenous course to a market established by teprotumumab. FDA review documents reveal important nuances around dose selection, durability, immunogenicity, safety, manufacturing and the product's competitive position.

Lumvoaveligrotug-vvzethyroid eye disease
Read Brief →
Regulatory Strategy12 min read

ER-100 Enters the Clinic: What FDA Will Need to See From Partial Epigenetic Reprogramming

ER-100 has moved partial epigenetic reprogramming from animal models into a first-in-human trial in glaucoma and NAION. Its development program will test not only whether retinal ganglion cell function can be restored, but also how FDA may evaluate a new therapeutic concept built around rejuvenating injured neurons rather than replacing them.

ER-100Gene TherapyEpigenetic Reprogramming
Read Brief →
Clinical Development14 min read

Novel Clinician-Reported Outcomes in FDA Approvals: Five Regulatory Lessons Since 2020

An assessment of FDA approvals since 2020 show that novel clinician-reported outcomes can support primary, secondary, and labeling claims, but only when the endpoint is interpretable in its specific context of use. Five applications illustrate how instrument design, rater standardization, estimands, and fallback evidence shape the regulatory outcome.

Clinical Outcome AssessmentsClinician-Reported OutcomesFDA
Read Brief →
Cell and Gene Therapy18 min read

iPSC-Derived Blood Stem Cells: Therapeutic Potential, Existing Care, and FDA Considerations

Induced pluripotent stem cell-derived blood stem cells could expand the sources available for hematopoietic transplantation and create a platform for genetic correction. Recent preclinical studies strengthen the rationale for durable and molecularly youthful grafts, while leaving human efficacy, safety, and manufacturability unresolved.

iPSCHematopoietic Stem CellsBlood Disorders
Read Brief →